GlassScriptPhysician profile
Jesus Garcia
NPI 1598293755
$10,702.08
in general payments reported to CMS, 2019-2025
14 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.62 · 2021: $1,951 · 2022: $152 · 2023: $107 · 2024: $8,184 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,500 · Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,500.00 |
| Food and Beverage | $1,071.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,625.41 | 2021-2024 | |
| Davol INC. | $141.37 | 2025 | Phasix Mesh |
| Biotissue Holdings INC. | $138.94 | 2025 | |
| Asensus Surgical, INC. | $136.33 | 2022 | |
| Kerecis Limited | $132.62 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Angiodynamics, INC. | $113.21 | 2021 | |
| Becton, Dickinson and Company | $107.33 | 2023 | Phasix Mesh |
| Medtronic, INC. | $102.49 | 2024 | Signia |
| Endogastric Solutions, INC | $80.72 | 2024 | Esophyx |
| Lilly USA, LLC | $46.25 | 2022-2024 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $25.67 | 2024 | Tremfya |
| Ardelyx, INC. | $24.12 | 2024 | Ibsrela |
| Amarin Pharma, INC. | $17.27 | 2019 | |
| Acell, INC. | $10.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.